



**Asian American Medical Group Limited**  
ABN 42 091 559 125  
6A Napier Road  
Gleneagles Hospital Annexe Block #02-37  
Singapore 258500  
Tel : (65) 6476 2088, Fax : (65) 6476 3088,

---

## AUSTRALIAN SECURITIES EXCHANGE ANNOUNCEMENT

---

19 April 2013

The Manager  
Companies Announcement Officer  
Australian Securities Exchange  
Electronic Lodgement

Dear Sir/Madam

### **ASX RELEASE – PLACEMENT OF NEW SHARES**

The Board of Directors (“the Board” or “the Directors”) of **Asian American Medical Group Limited** (“AAMG” or “the Company”) is pleased to announce that the Company has today entered into a placement agreement (“the Placement”) with RusSing Med Holdings Pte. Ltd. (“RMH” or “Subscriber”).

Incorporated in Singapore, RMH is a wholly-owned subsidiary of RusSing Holdings Pte Ltd (“RusSing”), which focuses on business opportunities deriving from growing relationships between Russia and Singapore. It has significant investments in various sectors such as Biotech, Pharmaceutical, Agriculture, Natural Resources, Green Technology and Real Estate. RusSing is led by Mr Evgeny Tugolukov, who is also the Honorary Business Representative of International Enterprise Singapore in Russia and Ukraine.

RMH will subscribe for 21,000,000 new shares issued at A\$0.17 per new Share or approximately 36.0% premium to the closing price of A\$0.125 as at 18 April 2013, representing 11.1% of the existing issued and paid-up share capital (“Share”). The Company will raise gross proceeds of A\$3,570,000 (approximately S\$4,533,900) from the Placement.

The Company intends to use the net proceeds from the Placement to finance its next phase of growth, primarily for the following purposes:

- (a) Capital expenditure and working capital (including marketing and branding) for the new Comprehensive Transplant Centre to be located in Singapore;
- (b) General working capital for expansion of existing operations;
- (c) Additional headcount and training programmes for the new Comprehensive Transplant Centre and existing operations; and
- (d) Other strategic alliances, market expansion and such business development plans when opportunities arise and as deemed fit by the Board of Directors.

Upon completion of the Placement:

- (a) The Company's issued share capital will be enlarged from 188,454,000 shares to 209,454,000 shares;
- (b) RusSing will effectively own slightly over 10.0% of the enlarged issued and paid-up share capital of the Company; and
- (c) The Company's cash position will increase by approximately S\$4.5 million to S\$7.8 million based on the cash and cash equivalents as at 31 March 2013.

Mr Tugolukov, President of RMH and RusSing, is expected to be appointed as Non-executive Director of the Company on or after completion of the Placement. RMH and Dr Tan Kai Chah have also both undertaken not to, directly and indirectly, sell, realise, transfer, assign, pledge, encumber and/or otherwise dispose of any part of their shares for a minimum period of twelve months from the date of completion of the Placement.

The Placement is less than 15% of the existing issued and paid-up shares capital of the Company and will not require shareholders' approval.

On behalf of the Board



**DARIO NAZZARI**

Company Secretary

About Asian American Medical Group

Asian American Medical Group (“AAMG”), formerly known as Asian Centre for Liver Diseases and Transplantation (“ACLDT”), was established in 1994 in Singapore. It is one of Asia’s foremost Liver Centres with out-patient facilities as well as a dedicated in-patient Liver Ward and Intensive Care Unit to complement its highly successful Living Donor Liver Transplantation (“LDLT”) Programme.

With the collaboration with The University of Pittsburgh Medical Center (“UPMC”), AAMG will extend to offer quality treatment beyond liver-related diseases and transplantation including kidney, blood and bone marrow transplant programmes through Asia’s first Comprehensive Transplant Centre (“CTC”).

AAMG is led by renowned hepatobiliary expert and liver transplant surgeon, Dr Tan Kai Chah (Dr K C Tan), who helped start the Liver Transplant Programme at the King’s College Hospital London, the UK. Dr Tan performed many pioneering operations in the UK including the first ‘split-liver’ transplant, first auxiliary liver graft and completed a pilot study of living donor liver transplantation.

AAMG is the first private medical centre in South-east Asia to have performed 205 living donor liver transplants as at 31 March 2013. On average, ACLDT treats 8,000 patients a year, of which over 90% are international patients from South-east Asia, South Asia, Indochina, the Middle East and Russia.

AAMG was listed on the Australian Securities Exchange in September 2009 (ASX:AJJ).

It opened its first overseas liver centre in Ho Chi Minh City, Vietnam, in September 2010.

For further information, please visit [www.asianlivercentre.com.sg](http://www.asianlivercentre.com.sg)

**Australia contact:**

Mr. Dario Nazzari, Company Secretary

Tel: +61 8 81100999

[dario@uhyhn.com.au](mailto:dario@uhyhn.com.au)

**Singapore contact (media):**

WeR1 Consultants Pte Ltd

Tel : +65 6737 4844

[josephine@wer1.net](mailto:josephine@wer1.net)